Sign in

You're signed outSign in or to get full access.

Tanmay

Research Analyst at JPMorgan Chase & Co.

Tanmay Khandelwal is an Executive Director and Senior Equity Research Analyst at JPMorgan Chase & Co., specializing in the coverage of Indian IT services companies. He covers major firms such as Infosys, Tata Consultancy Services, Wipro, and HCL Technologies, and is recognized for his insightful stock recommendations that have earned him consistent top analyst rankings on platforms like Institutional Investor and TipRanks. Tanmay began his career in equity research at Credit Suisse in 2013 before joining JPMorgan in 2017, where he has maintained a strong track record, achieving a success rate above 65% and generating noteworthy returns for investors. He is a CFA charterholder and holds relevant SEBI/NISM analyst certifications, reflecting his professional commitment and expertise in the field.

Tanmay's questions to Legend Biotech (LEGN) leadership

Question · Q3 2025

Tanmay, on behalf of Jessica Fye, requested an update on the percentage of CARVYKTI patients receiving outpatient administration and the revenue contribution split between earlier and later lines of therapy.

Answer

Alan Bash, President of CARVYKTI, reported that approximately 50% of patients are currently treated in an outpatient setting, with expectations for this percentage to grow. He also noted that about 60% of CARVYKTI scripts originate from the second through fourth line patient population, with the third line showing the fastest growth.

Ask follow-up questions

Fintool

Fintool can predict Legend Biotech logo LEGN's earnings beat/miss a week before the call